Objective: Since 2010, gemcitabine and cisplatin have been considered standard first-line treatment in patients with advanced biliary tract cancer. Many centers have replaced cisplatin with oxaliplatin, which seems to obtain similar results. While first-line treatment has been well established, there are no phase III trials supporting second-line treatment, and the phase II trials with chemotherapy do not show any clear benefit. In this study, we investigated the effect of adding bevacizumab to chemotherapy in second-line treatment. Methods: From November 2013 to January 2016, 50 patients with advanced biliary tract cancer were enrolled in this prospective phase II trial. All patients had received a gemcitabine-platinum combination as first-line treatment. The patients received capecitabine, irinotecan, gemcitabine, and bevacizumab in a 2-week schedule as second-line treatment. Results: The combination was well tolerated with a median progression-free survival of 3.6 months, a median overall survival of 6.4 months, and a response rate of 6%. Conclusion: The combination of capecitabine, irinotecan, gemcitabine, and bevacizumab as a second-line treatment for advanced biliary tract cancer is well tolerated but with a modest, if any, benefit.

Keywords:
Second-line treatment, Advanced biliary tract cancer
1.
Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2.
Gebbia V, Giuliani F, Maiello E, et al: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001;19:4089-4091.
3.
Kornek GV, Schuell B, Laengle F, et al: Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial. Ann Oncol 2004;15:478-483.
4.
Glimelius B, Hoffmann K, Sjoden PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
5.
Rao S, Cunningham D, Hawkins RE, et al: Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005;92:1650-1654.
6.
Ducreux M, Van Cutsem E, Van Laethem JL, et al: A randomized phase II trial of weekly high-dose 5-fluoruracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma. Eur J Cancer 2005;41:398-403.
7.
Hollebecque A, Bouche O, Romano O, et al: Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. Chemotherapy 2010;56:234-238.
8.
Sohn BS, Yuh YJ, Kim KH, et al: Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder and ampulla of Vater. Tumori 2013;99:139-144.
9.
Wu CE, Hsu HC, Shen WC, et al: Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis. Chang Gung Med J 2012;35:420-427.
10.
Sharma A, Dwary AD, Mohanti BK, et al: Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010;28:4581-4586.
11.
Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902.
12.
Valle J, Wasan H, Palmer D, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;363:1273-1281.
13.
Andre T, Tournigand C, Rosmorduc O, et al: Gemcitabine combined with oxaliplatin in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343.
14.
Lee J, Park S, Chang H, et al: Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicenter open label randomized phase III study. Lancet 2012;13:181-188.
15.
Larsen FO, Mellergaard AH, Hoegdall D, Jensen LH: Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma. Acta Oncol 2014;53:1448-1450.
16.
Lamarca A, Hubner RA, Ryder WD, Valle JW: Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014;25:2328-2338.
17.
Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, et al: Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer 2015;121:3290-3297.
18.
Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, et al: Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res 2015;34:156-163.
19.
Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
20.
Letelier P, Garcia P, Leal P, Ili C, Buchegger K, Riquelme I, et al: Immunohistochemical expression of vascular endothelial growth factor A in advanced gallbladder carcinoma. Appl Immunohistochem Mol Morphol 2014;22:530-536.
21.
Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008;98:418-425.
22.
Mullany S, Svingen PA, Kaufmann SH, et al: Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN 38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998;42:391-399.
23.
Hurwitz H, Fehrenbacker L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
24.
Neoptolemos JP, Palmer DH, Ghaneh P, et al: Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomized, phase 3 trial. Lancet 2017;389:1011-1024.
25.
Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;11:2059-2069.
26.
Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
27.
Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin fluorouracil and leucovorin (FOLFOX 4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
28.
Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
29.
Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al: Efficacy and safety of gemcitabine, oxaliplatin and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010;11:48-54.
30.
Iyer RV, Pokuri VK, Groman A, Ma WW, Malhotra U, Lancu DM: A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer. Am J Clin Oncol 2016, Epub ahead of print.
31.
Kemeny NE, Schwartz L, Gonen M, Yopp A, Gultekin D, D'Angelica MI, et al: Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 2011;80:153-159.
32.
Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F: FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015;21:2096-2101.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.